Aclarion, Inc. (ACON)

NASDAQ: ACON · IEX Real-Time Price · USD
0.800
+0.200 (33.33%)
Feb 6, 2023, 1:36 PM EST - Market open
33.33%
Market Cap 6.49M
Revenue (ttm) 49,901
Net Income (ttm) -9.41M
Shares Out 7.82M
EPS (ttm) -7.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 74,160
Open 0.720
Previous Close 0.600
Day's Range 0.630 - 0.847
52-Week Range 0.380 - 4.050
Beta n/a
Analysts Buy
Price Target 3.06 (+282.5%)
Earnings Date n/a

About ACON

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California. [Read more]

Sector Healthcare
IPO Date Apr 22, 2022
Employees 3
Stock Exchange NASDAQ
Ticker Symbol ACON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ACON stock is "Buy." The 12-month stock price forecast is $3.06, which is an increase of 282.50% from the latest price.

Price Target
$3.06
(282.50% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers ...

6 days ago - GlobeNewsWire

Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...

2 weeks ago - GlobeNewsWire

Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event

Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"),  a healthcare technology company that is leveraging biomarkers...

2 weeks ago - Newsfile Corp

Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire  -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarke...

1 month ago - GlobeNewsWire

Aclarion's Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.

1 month ago - GlobeNewsWire

Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor

Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.

1 month ago - GlobeNewsWire

Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker

Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration.

2 months ago - GlobeNewsWire

Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV

BROOMFIELD, CO / ACCESSWIRE / October 25, 2022 / Aclarion, Inc. (NASDAQ:ACON)(NASDAQ:ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary...

3 months ago - Accesswire

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

BROOMFIELD, CO / ACCESSWIRE / October 24, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augm...

3 months ago - Accesswire

Aclarion To Present at The LD Micro Main Event XV

Presentation on Tuesday, October 25th at 9:00 AM PTBroomfield, Colorado--(Newsfile Corp. - October 12, 2022) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcar...

4 months ago - Newsfile Corp

Aclarion Announces Participation at the NASS 37th Annual Meeting

Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022 NociscanTM is the first evidence-supported SaaS platform to objectively analyze intradiscal pain Nociscan bridges major...

4 months ago - Accesswire

John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of NociscanTM solution BROOMFIELD, CO / ACCESSWIRE / O...

4 months ago - Accesswire

Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain

NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter BEST to study the role of biomarkers in optimizing the treatment of chronic low back pain NociscanTM to be com...

5 months ago - Accesswire

Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference

Broomfield, Colorado--(Newsfile Corp. - August 4, 2022) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and...

6 months ago - Newsfile Corp

Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan

Initial findings from the EVAL study are expected to be released in Q4 2022 Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patients Promising initial...

7 months ago - Accesswire

Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain

Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years Two Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank ...

8 months ago - Accesswire